BioAtla (BCAB) CFO awarded 240,000 restricted stock units, total holdings 530,196 shares

Rhea-AI Filing Summary

Vasquez Christian reported acquisition or exercise transactions in this Form 4 filing.

BioAtla, Inc. Chief Financial Officer Christian Vasquez received a grant of 240,000 shares of Common Stock in the form of time-based restricted stock units. These units carry no purchase price and increase his direct holdings to 530,196 shares after the award.

The RSU grant vests over time: 25% of the shares vest on March 10, 2027, with an additional 6.25% vesting on the last day of each May, August, November, and February thereafter, as long as he remains in service through each vesting date.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Vasquez Christian

Role Chief Financial Officer

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	240,000	$0.00	--

Holdings After Transaction: Common Stock — 530,196 shares (Direct)

Footnotes (1)

1. [object Object]

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Vasquez Christian

(Last) (First) (Middle)

C/O BIOATLA, INC. 11085 TORREYANA ROAD

(Street)

SAN DIEGO CA 92121

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
BioAtla, Inc. [ BCAB ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
03/10/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/10/2026		A		240,000(1)	A	$0	530,196	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents shares of Common Stock underlying a time-based restricted stock unit award ("RSU"). The RSU will vest as to 25% of the total number of shares on March 10, 2027, and thereafter, 6.25% of the total number of shares subject to the RSU shall vest on the last day of each May, August, November and February, subject to the reporting person's continued service through the applicable vesting date.

	Christian Vasquez	03/12/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did BioAtla (BCAB) report for its CFO?

BioAtla reported that CFO Christian Vasquez received a grant of 240,000 time-based restricted stock units of Common Stock. This is a compensation-related award, not an open‑market purchase or sale, and increases his direct holdings to 530,196 shares following the transaction.

How do the 240,000 RSUs granted to BioAtla (BCAB) CFO vest?

The 240,000 RSUs vest gradually over time. Twenty‑five percent vest on March 10, 2027, and the remaining units vest in 6.25% increments on the last day of each May, August, November, and February, subject to the CFO’s continued service through each vesting date.

Did the BioAtla (BCAB) CFO pay anything for the 240,000 RSU grant?

The filing shows a price per share of $0.00 for the 240,000 RSUs, indicating they were granted as equity compensation. This means the CFO did not buy these shares on the market; they are awarded subject to future vesting conditions.

How many BioAtla (BCAB) shares does the CFO hold after this RSU award?

After the 240,000‑share RSU grant, CFO Christian Vasquez is reported to beneficially own 530,196 shares of BioAtla Common Stock directly. This figure reflects his position immediately following the reported compensation award in the Form 4 filing.

Is the BioAtla (BCAB) CFO’s RSU grant an open‑market trade?

No. The Form 4 classifies the transaction with code “A” as a grant or award acquisition. It represents time‑based restricted stock units granted as compensation, rather than shares bought or sold in open‑market trading by the CFO.